At the 3rd World Keratoconus Congress in Florence, April 16-18 2026, Regensight brought together a panel of leading experts to explore theranostic-guided Keratoconus treatment.
The symposium offered a unique opportunity to gain a clear, structured view of where Keratoconus management is heading: from the principles of theranostics to data-driven vs empirical CXL approaches from real-time control of CXL photo-chemistry to the supporting clinical evidence and the next frontier: theranostic-guided corneal UV photo-reshaping, moving beyond stabilization toward precision corneal reshaping without incisions.
Don’t miss the chance to dive deeper into this paradigm shift in Keratoconus treatment.
Another advance was announced by Dr. Edoardo Grosso, the Co-inventor of the GROSSO® Reshaper, as well as the Co-founder and Chief Medical Officer of RECORNEA. He gave an oral presentation during the “EYESEE” arena poster presentation at the 3rd World Keratoconus Congress, April 16-18, 2026.
The presentation “Interim results of the First In Human study for the first nickel-titanium GROSSO® Reshaper for treatment of advanced Keratoconus” discussed the safety and efficacy data of the GROSSO® Reshaper, with this data providing the initial clinical support of the safety and therapeutic potential of the GROSSO® Reshaper for treatment of patients with advanced Keratoconus.
.png)
![[Video] Adverse Eye Rubbing in Keratoconus](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg4HRiK6MvFtia856foWYkBDP2bCVe0NB-S445VtbzLVYY19KJ6Pma-J-xabIQgjfE3RyTgr5C7Y9IvGs6PZ2ofcR13vtnGSwqghFJv40mZdjUD4VyOfjGN03Fhyphenhyphenziai2VNOASlDExTi77TdfDrh2yKeS735QlfIwwLZhn0xilsHeLiGDvhshth384ZzgBu/w72-h72-p-k-no-nu/keratoconus-pathogenesis.jpg)
